Answers are grounded in this paper and cite their sources.
This study found that neoadjuvant chemoimmunotherapy was superior to neoadjuvant chemotherapy across surgical, pathological, and efficacy outcomes. These findings suggest that patients with resectable NSCLC with tumor PD-L1 levels less than 1% may have an event-free survival benefit with neoadjuvant chemoimmunotherapy.
No takes yet. Share an insight, caveat, or question.
Sorin et al. (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: